Yahoo Finance Director N Coles Sells 50,000 Shares of Cerevel Therapeutics Holdings Inc (CERE)
Cerevel Therapeutics Holdings Inc (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, has reported an insider sale according to the latest SEC filings. Director N Coles has sold 50,000 shares of the company on March 4, 2024. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this SEC Filing.Over the past year, the insider has sold a total of 552,506 shares of Cerevel Therapeutics Holdings Inc and has not made any purchases of the stock. This recent sale continues a trend observed over the past year, where insider transactions have been predominantly sales. In the same period, there have been 27 insider sells and 6 insider buys among Cerevel Therapeutics Holdings Inc insiders.
On the day of the insider's recent sale, shares of Cerevel Therapeutics Holdings Inc were trading at $41.01 each, placing the company's market capitalization at $7.500 billion.Cerevel Therapeutics Holdings Inc is focused on discovering and developing new therapies for neuroscience diseases, including Parkinson's disease, epilepsy, schizophrenia, and Alzheimer's disease. The company leverages its deep understanding of neurocircuitry together with advanced chemistry and pharmacology to develop therapies aimed at improving the lives of those suffering from neurological disorders.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
